Dialysis Australia is a respected and experienced provider of home-based dialysis services.  As an enabler of in-home dialysis care, Dialysis Australia is changing the landscape for people living with Chronic Kidney Disease by allowing a greater number of patients to dialyse in the comfort of their own home.

The Assisted Home Haemodialysis (AHHD) model of care – where an experienced nurse can administer full dialysis treatment or offer cannulation support, was pioneered by Dialysis Australia in bringing hospital care into patients’ own homes, providing them with choice and flexibility in where they receive their care. The benefits of receiving dialysis at home include:

  • Choice in treatment times
  • Improved quality of life
  • Elimination of travel costs
  • Improved morbidity and mortality

Providing excellence in Healthcare founded on the principles of quality of care, care for the patient, integrity of staff and respect for all, Dialysis Australia delivers “Care with compassion and commitment” making us your home dialysis experts.



Otsuka is a global company with an international network of 189 companies, 47,000 employees, 47 affiliated research institutes and 171 manufacturing sites. Otsuka operates in more than 80 countries and regions across Asia-Pacific, America, Europe, and the Middle East. The people at Otsuka are dedicated to creating new products for better health worldwide.

Underpinning these words is our commitment to:

  • Creating unique and innovative products
  • Improving health and well-being
  • Contributing to the lives of people worldwide



Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Twentynine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines.

Founded in 1896, the Roche Group is headquartered in Basel, Switzerland, and is active in over 100 countries. In 2016 Roche employed more than 94,000 people worldwide and invested CHF 9.9 billion in research and development, including almost AUD 37 million in pharmaceuticals in Australia. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry eight years in a row by the Dow Jones Sustainability Indices.

Roche’s pharmaceutical division in Australia is dedicated to the clinical development, registration, sales, marketing and distribution of innovative pharmaceutical medicines. Australian patients have access to about 40 Roche medicines, and the company is the leading provider of cancer medicines in Australia by sales.



Fresenius Medical Care is the world’s leading provider of products and services for people with chronic kidney failure.
Our mission is simple – To create a future worth living for patients worldwide, every day. Around 3.4 million patients with this disease worldwide regularly undergo dialysis treatment and every 0.6 seconds Fresenius Medical Care provide a dialysis treatment somewhere on the globe.
We care for more than 336,000 patients in our global network of over 3,900 dialysis clinics. At the same time, we operate 42 production sites on all continents, providing dialysis products such as dialysis machines, dialyzers and related disposables. Fresenius Medical Care has been developing and producing dialysis products for more than four decades.

The Fresenius Medical Care family employs around 112,000 people across 50 countries.
Locally, our ANZ team supports dialysis products and services to public and private hospitals for patients with chronic or acute kidney failure. We are also one of the largest private providers, caring for patients across a network of 24 dialysis clinics as well as home therapies programs.
Our global and local strategy is geared toward sustainable growth. We aim to continuously improve the quality of life of patients with kidney disease by offering innovative products and treatment concepts of the highest quality.



The ASM is hosted by Australian and New Zealand Society of Nephrology.

The aims of the Society are to promote and support the study of the kidney and urinary tract in health and disease, and to ensure the highest professional standards for the practice of nephrology in Australia and New Zealand.

Conference Managers

Please contact the team at Conference Design with any questions regarding the Annual Scientific Meeting

© 2015 - 2016 Conference Design Pty Ltd